In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 3107-3111

  Cuenca Estrella, Manuel ^a   Gomez Lopez, Alicia ^a   Mellado, Emilia ^a   Garcia Effron, Guillermo ^a   Rodriguez Tudela, Juan L ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA GLABRATA; CANDIDA TROPICALIS; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; DRUG RESISTANCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YEAST;

ANTIFUNGAL AGENTS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; THIAZOLES; TRIAZOLES; YEASTS;

EID: 3342910270     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.3107-3111.2004     Document Type: Article

References (29)

1. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:1193-1199.
2. Arikan, S., and J. H. Rex. 2002. Ravuconazole Eisai/Bristol-Myers Squibb. Curr. Opin. Investig. Drugs 3:555-561.
3. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
4. Carrillo, A. J., and J. Guarro. 2001. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob. Agents Chemother. 45:2151-2153.
5. Clemons, K. V., M. Martinez, L. Calderon, and D. A. Stevens. 2002. Efficacy of ravuconazole in treatment of systemic murine histoplasmosis. Antimicrob. Agents Chemother, 46:922-924.
6. Clemons, K. V., and D. A. Stevens. 2001. Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice. Antimicrob. Agents Chemother. 45:3433-3436.
7. Cuenca-Estrella, M., W. Lee-Yang, M. A. Ciblak, B. A. Arthington-Skaggs, E. Mellado, D. W. Warnock, and J. L. Rodriguez-Tudela. 2002. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob. Agents Chemother. 46:3644-3647.
8. Diekema, D. J., S. A. Messer, R. J. Hollis, R. N. Jones, and M. A. Pfaller. 2003. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J. Clin. Microbiol. 41:3623-3626.
9. Espinel-Ingroff, A., A. Fothergill, J. Peter, M. G. Rinaldi, and T. J. Walsh. 2002. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J. Clin. Microbiol. 40:3204-3208.
10. Fung-Tomc, J. C., E. Huczko, B. Minassian, and D. P. Bonner. 1998. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 42:313-318.
11. Fung-Tomc, J. C., T. C. White, B. Minassian, E. Huczko, and D. P. Bonner. 1999. In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole. Diagn. Microbiol. Infect. Dis. 35:163-167.
12. Hoffman, H. L., E. J. Ernst, and M. E. Klepser. 2000. Novel triazole antifungal agents. Expert. Opin. Investig. Drugs 9:593-605.
13. Kirkpatrick, W. R., S. Perea, B. J. Coco, and T. F. Patterson. 2002. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J. Antimicrob. Chemother. 49:353-357.
14. Kurtzman, C. P., and J. W. Fell. 1998. The yeasts. A taxonomic study. Elsevier, Amsterdam, The Netherlands.
15. Laverdiere, M., D. Hoban, C. Restieri, and F. Habel. 2002. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother. 50:119-123.
16. Mikamo, H., X. H. Yin, Y. Hayasaki, M. Satoh, and T. Tamaya. 2001. Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model. Chemotherapy (Tokyo) 47:377-380.
17. Mikamo, H., X. H. Yin, Y. Hayasaki, Y. Shimamura, K. Uesugi, N. Fukayama, M. Satoh, and T. Tamaya. 2002. Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy (Tokyo) 48:7-9.
18. Minassian, B., E. Huczko, T. Washo, D. Bonner, and J. Fung-Tomc. 2003. In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin. Microbiol. Infect. 9:1250-1252.
19. Moore, C. B., C. M. Walls, and D. W. Denning. 2000. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob. Agents Chemother. 44:441-443.
20. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Paphitou, N. I., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chen, and J. H. Rex. 2002. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother. 46:1144-1146.
22. Petraitis, V., R. Petraitiene, A. A. Sarafandi, A. M. Kelaher, C. A. Lyman, H. E. Casler, T. Sein, A. H. Groll, J. Bacher, N. A. Avila, and T. J. Walsh. 2003. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187:1834-1843.
23. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, and R. N. Jones. 2004. In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. 48:101-105.
24. Pfaller, M. A., S. A. Messer, R. J. Hollis, and R. N. Jones. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46:1032-1037.
25. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
26. Rodriguez-Tudela J. L., F. Barchiesi, J. Bille, E. Chryssanthou, M. Cuenca-Estrella, D. Denning, J. P. Donnelly, B. Dupont, W. Fegeler, C. Moore, M. Richardson, P. E. Verweij, and Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2003. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin. Microbiol. Infect 9:I-VIII.
27. Rodriguez-Tudela, J. L., F. Martin-Diez, M. Cuenca-Estrella, L. Rodero, Y. Carpintero, and B. Gorgojo. 2000. Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrob. Agents Chemother. 44:400-404.
28. Serena, C., M. Ortoneda, J. Capilla, F. J. Pastor, D. A. Sutton, M. G. Rinaldi, and J. Guarro. 2003. In vitro activities of new antifungal agents against Chaetomium spp. and inoculum standardization. Antimicrob. Agents Chemother. 47:3161-3164.
29. Yamazumi, T., M. A. Pfaller, S. A. Messer, A. Houston, R. J. Hollis, and R. N. Jones. 2000. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:2883-2886.